<DOC>
	<DOC>NCT00095173</DOC>
	<brief_summary>The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.</brief_summary>
	<brief_title>BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis of Juvenile Rheumatoid Arthritis or Juvenile Idiopathic Arthritis; Current active arthritis; Failed treatment with at least one disease modifying antirheumatic drug (DMARD); Subjects must discontinue use of any DMARD other than methotrexate prior to the first dose of study medication Presence of infection or history of frequent acute or chronic infections; Joint replacement surgery required during the study or history of surgery on more than 5 joints; Live vaccines within 3 months of the first dose of study medication; Unresolved serious bacterial infection or chronic bacterial infection; Subjects who currently have intermittent fever due to JRA/JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
</DOC>